サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1679169

化学療法薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2025年～2032年

Chemotherapy Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 278 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
化学療法薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2025年～2032年
出版日: 2025年03月13日
発行: Persistence Market Research
ページ情報: 英文 278 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の化学療法薬市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・促進要因・課題など、重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。この調査レポートは、2025年から2032年までの世界の化学療法薬市場の予測成長軌道を概説する独占データと統計を掲載しています。

主な洞察

  • 化学療法薬の市場規模（2025年）：561億米ドル
  • 予測市場規模（2032年）：1,025億米ドル
  • 世界市場成長率（CAGR 2025年から2032年まで）：9.0%

化学療法薬市場- レポート範囲：

化学療法薬はがん治療に不可欠であり、急速に分裂するがん細胞を標的として排除することで効果を発揮します。これらの薬剤は、手術、放射線療法、免疫療法などの他の治療と組み合わせて使用され、患者の予後を向上させる。化学療法薬市場は、アルキル化剤、代謝拮抗剤、分裂阻害剤、トポイソメラーゼ阻害剤など、さまざまな種類の薬剤を提供し、病院、専門がんセンター、在宅医療の現場に対応しています。市場成長の原動力は、がん罹患率の増加、ヘルスケア支出の増加、薬剤製剤の進歩による治療効果の向上と副作用の軽減です。

市場成長の促進要因：

世界の化学療法薬市場は、世界のがん罹患率の増加、薬剤開発の進展、標的治療薬に対する需要の高まりなど、いくつかの重要な要因によって推進されています。喫煙、食生活の乱れ、環境汚染などの生活習慣に関連する危険因子と相まって高齢化人口が増加していることが、がんの罹患率上昇の一因となっており、化学療法治療の需要に拍車をかけています。さらに、併用療法や個別化医療の開発により患者の転帰が改善され、化学療法薬の採用が広がっています。がん治療のインフラ整備や研究資金の増加を目的とした政府の取り組みは、市場拡大をさらに後押ししています。

市場抑制要因：

有望な成長が見込まれるものの、化学療法薬市場は薬物毒性、高い治療費、厳しい規制要件に関する課題に直面しています。吐き気、脱毛、免疫抑制など、化学療法に伴う副作用はしばしば治療中止につながり、市場導入に影響を与えます。さらに、特に中低所得国では、化学療法薬の高額な価格と患者の経済的負担が市場浸透の大きな障壁となっています。また、医薬品承認プロセスの長期化や厳しい安全性ガイドラインへの準拠など、規制上の課題も市場拡大の妨げとなっています。これらの課題に対処するには、支持療法への投資拡大、費用対効果の高い薬剤処方、規制の調和が必要です。

市場機会：

化学療法薬市場は、技術の進歩、ヘルスケアアクセスの拡大、研究開発投資の増加によって大きな成長機会がもたらされます。副作用を軽減し有効性を高めた標的化学療法薬の開発は、技術革新の主要分野です。さらに、バイオシミラーや化学療法薬のジェネリック医薬品の採用拡大により、購入しやすい価格帯が改善され、市場拡大が期待されます。アジア太平洋とラテンアメリカの新興市場は、ヘルスケア・インフラ投資の増加とがん治療オプションに対する意識の高まりにより、有利な機会を提供しています。企業がこうした機会を活用し、市場でのリーダーシップを維持するためには、戦略的提携やバイオテクノロジー企業とのパートナーシップ、ドラッグデリバリー機構の継続的な進歩が不可欠です。

本レポートで扱う主な質問

  • 世界の化学療法薬市場の成長を促す主な要因は何か？
  • さまざまなヘルスケア環境で化学療法を採用する原動力となっている薬剤の種類と用途は何か？
  • 技術の進歩は化学療法薬市場の競合情勢をどのように変えているか？
  • 化学療法薬市場に貢献している主要企業はどこで、市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の化学療法薬市場における新たな動向と将来の見通しは？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • マクロ経済要因
    • 世界のセクター別見通し
    • 世界のGDP成長見通し
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

  • 製品採用分析
  • 規制状況
  • 疾病疫学
  • バリューチェーン分析
  • 主要な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の化学療法薬市場の見通し：

  • 主なハイライト
    • 市場規模と前年比成長率
    • 絶対的収益機会
  • 市場規模の分析と予測
    • 過去の市場規模分析、2019～2024年
    • 現在の市場規模の分析と予測、2024～2032年
  • 世界の化学療法薬市場の見通し：薬剤クラス
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、薬剤クラス別、2019～2024年
    • 現在の市場規模の分析と予測、薬剤クラス別、2024～2032年
      • アルキル化剤
      • 代謝拮抗物質
      • 抗腫瘍抗生物質
      • トポイソメラーゼ阻害剤
      • 有糸分裂阻害剤
      • 植物アルカロイド
      • コルチコステロイド
      • その他抗腫瘍薬
    • 市場の魅力分析：医薬品クラス
  • 世界の化学療法薬市場の見通し：適応症
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、適応症別、2019年～2024年
    • 現在の市場規模の分析と予測、適応症別、2024～2032年
      • 肺がん
      • 乳がん
      • 大腸がん
      • 前立腺がん
      • 白血病
      • リンパ腫
      • 卵巣がん
      • 膵臓がん
      • その他
    • 市場の魅力分析：適応症
  • 世界の化学療法薬市場の見通し：投与経路
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、投与経路別、2019年～2024年
    • 現在の市場規模の分析と予測、投与経路別、2024～2032年
      • オーラル
      • 非経口
      • その他
    • 市場の魅力分析：投与経路
  • 世界の化学療法薬市場の見通し：剤形
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、剤形別、2019年～2024年
    • 現在の市場規模の分析と予測、剤形別、2024～2032年
      • カプセル/錠剤
      • 注射
      • その他
    • 市場の魅力分析：剤形
  • 世界の化学療法薬市場の見通し：流通チャネル
    • イントロダクション/主な調査結果
    • 過去の市場規模分析、流通チャネル別、2019～2024年
    • 現在の市場規模の分析と予測、流通チャネル別、2024～2032年
      • 小売薬局
      • 病院薬局
      • 腫瘍科クリニックと点滴センター
      • その他
    • 市場の魅力分析：流通チャネル

第5章 世界の化学療法薬市場の見通し：地域

  • 主なハイライト
  • 地域別市場規模の過去分析、2019～2024年
  • 現在の市場規模の分析と予測、地域別、2024～2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の化学療法薬市場の見通し：

第7章 欧州の化学療法薬市場の見通し：

第8章 東アジアの化学療法薬市場の見通し：

第9章 南アジアおよびオセアニアの化学療法薬市場の見通し：

第10章 ラテンアメリカの化学療法薬市場の見通し：

第11章 中東およびアフリカの化学療法薬市場の見通し：

第12章 競合情勢

  • 市場シェア分析、2024年
  • 市場構造
    • 市場別の競合激化マップ
    • 競合ダッシュボード
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • F. Hoffmann-La Roche Ltd
    • Celgene Corp
    • Novartis AG
    • Bristol-Myers Squibb Co
    • Johnson &Johnson
    • Sanofi
    • Pfizer Inc.
    • Eli Lilly &Company
    • ImClone Systems Inc.
    • GlaxoSmithKline
    • AstraZeneca
    • Schering-Plough
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Teva Pharmaceuticals Industries
    • E. Hoffmann-La Roche Ltd
    • Merck &Co. Inc.
    • Chemo Espana SL
    • Amgen Inc
    • Bayer AG
    • Takeda Pharmaceutical Company Limited

第13章 付録

  • 調査手法
  • 調査の前提
  • 頭字語と略語
目次
Product Code: PMRREP27301

Persistence Market Research has recently released a comprehensive report on the worldwide market for chemotherapy drugs. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global chemotherapy drugs market from 2025 to 2032.

Key Insights:

  • Chemotherapy Drugs Market Size (2025E): US$ 56.1Bn
  • Projected Market Value (2032F):US$ 102.5Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.0%

Chemotherapy Drugs Market - Report Scope:

Chemotherapy drugs are essential in cancer treatment, working by targeting and eliminating rapidly dividing cancer cells. These drugs are used in combination with other treatments, including surgery, radiation therapy, and immunotherapy, to enhance patient outcomes. The chemotherapy drugs market caters to hospitals, specialty cancer centers, and homecare settings, offering a range of drug types, including alkylating agents, antimetabolites, mitotic inhibitors, and topoisomerase inhibitors. Market growth is driven by increasing cancer prevalence, rising healthcare expenditures, and advancements in drug formulations, enhancing treatment efficacy and reducing side effects.

Market Growth Drivers:

The global chemotherapy drugs market is propelled by several key factors, including the increasing global burden of cancer, advancements in drug development, and the rising demand for targeted therapies. The growing aging population, coupled with lifestyle-related risk factors such as smoking, poor diet, and environmental pollution, contributes to the rising incidence of cancer, fueling the demand for chemotherapy treatments. Additionally, the development of combination therapies and personalized medicine has improved patient outcomes, leading to wider adoption of chemotherapy drugs. Government initiatives aimed at improving cancer care infrastructure and increasing research funding further drive market expansion.

Market Restraints:

Despite promising growth prospects, the chemotherapy drugs market faces challenges related to drug toxicity, high treatment costs, and stringent regulatory requirements. The adverse side effects associated with chemotherapy, such as nausea, hair loss, and immune suppression, often lead to treatment discontinuation, impacting market adoption. Additionally, the high cost of chemotherapy drugs and the financial burden on patients, particularly in low- and middle-income countries, pose significant barriers to market penetration. Regulatory challenges, including lengthy drug approval processes and compliance with stringent safety guidelines, further hinder market expansion. Addressing these challenges requires increased investment in supportive care, cost-effective drug formulations, and regulatory harmonization.

Market Opportunities:

The chemotherapy drugs market presents significant growth opportunities driven by technological advancements, expanding healthcare access, and increasing R&D investments. The development of targeted chemotherapy drugs with reduced side effects and enhanced efficacy is a key area of innovation. Additionally, the growing adoption of biosimilars and generic chemotherapy drugs is expected to improve affordability and expand market reach. Emerging markets in Asia-Pacific and Latin America offer lucrative opportunities due to rising healthcare infrastructure investments and increasing awareness about cancer treatment options. Strategic collaborations, partnerships with biotechnology firms, and continuous advancements in drug delivery mechanisms are essential for companies to capitalize on these opportunities and maintain market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the chemotherapy drugs market globally?
  • Which drug types and applications are driving chemotherapy adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the chemotherapy drugs market?
  • Who are the key players contributing to the chemotherapy drugs market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global chemotherapy drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global chemotherapy drugs market, including Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, and Novartis AG, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced chemotherapy solutions, including targeted therapies, antibody-drug conjugates, and nanoparticle-based drug delivery systems, catering to diverse patient needs and clinical requirements. Collaborations with research institutions, hospitals, and regulatory agencies facilitate market access and promote drug adoption. Moreover, emphasis on clinical research, precision medicine, and patient-centric approaches fosters market growth and enhances treatment outcomes in the evolving oncology landscape.

Key Companies Profiled:

  • Pfizer Inc.
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Sanofi S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Amgen Inc.
  • Bayer AG

Key Segments of Chemotherapy Drugs Industry Research

By Drug Class:

  • Alkylating Agents
  • Antimetabolites
  • Anti-tumour Antibiotics
  • Topoisomerase Inhibitors
  • Mitotic Inhibitors
  • Plant Alkaloids
  • Corticosteroids
  • Miscellaneous Antineoplastic

By Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Leukemia
  • Lymphoma
  • Ovarian Cancer
  • Pancreatic Cancer

By Route of Administration:

  • Oral
  • Parenteral

By Dosage Form:

  • Capsules/Tablets
  • Injections

By Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Oncology Clinics & Infusion Centers

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Chemotherapy Drugs Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Disease Epidemiology
  • 3.4. Value Chain Analysis
  • 3.5. Key Deals and Mergers
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Global Chemotherapy Drugs Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
  • 4.3. Global Chemotherapy Drugs Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
      • 4.3.3.1. Alkylating Agents
      • 4.3.3.2. Antimetabolites
      • 4.3.3.3. Anti-tumour Antibiotics
      • 4.3.3.4. Topoisomerase Inhibitors
      • 4.3.3.5. Mitotic Inhibitors
      • 4.3.3.6. Plant Alkaloids
      • 4.3.3.7. Corticosteroids
      • 4.3.3.8. Miscellaneous Antineoplastic
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Chemotherapy Drugs Market Outlook: Indication
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
      • 4.4.3.1. Lung Cancer
      • 4.4.3.2. Breast Cancer
      • 4.4.3.3. Colorectal Cancer
      • 4.4.3.4. Prostate Cancer
      • 4.4.3.5. Leukemia
      • 4.4.3.6. Lymphoma
      • 4.4.3.7. Ovarian Cancer
      • 4.4.3.8. Pancreatic Cancer
      • 4.4.3.9. Others
    • 4.4.4. Market Attractiveness Analysis: Indication
  • 4.5. Global Chemotherapy Drugs Market Outlook: Route of Administration
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
      • 4.5.3.1. Oral
      • 4.5.3.2. Parenteral
      • 4.5.3.3. Others
    • 4.5.4. Market Attractiveness Analysis: Route of Administration
  • 4.6. Global Chemotherapy Drugs Market Outlook: Dosage Form
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Dosage Form, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
      • 4.6.3.1. Capsules/Tablets
      • 4.6.3.2. Injections
      • 4.6.3.3. Others
    • 4.6.4. Market Attractiveness Analysis: Dosage Form
  • 4.7. Global Chemotherapy Drugs Market Outlook: Distribution Channel
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
      • 4.7.3.1. Retail Pharmacies
      • 4.7.3.2. Hospital Pharmacies
      • 4.7.3.3. Oncology Clinics & Infusion Centers
      • 4.7.3.4. Others
    • 4.7.4. Market Attractiveness Analysis: Distribution Channel

5. Global Chemotherapy Drugs Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Chemotherapy Drugs Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Indication
    • 6.2.4. By Route of Administration
    • 6.2.5. By Dosage Form
    • 6.2.6. By Distribution Channel
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 6.4.1. Alkylating Agents
    • 6.4.2. Antimetabolites
    • 6.4.3. Anti-tumour Antibiotics
    • 6.4.4. Topoisomerase Inhibitors
    • 6.4.5. Mitotic Inhibitors
    • 6.4.6. Plant Alkaloids
    • 6.4.7. Corticosteroids
    • 6.4.8. Miscellaneous Antineoplastic
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 6.5.1. Lung Cancer
    • 6.5.2. Breast Cancer
    • 6.5.3. Colorectal Cancer
    • 6.5.4. Prostate Cancer
    • 6.5.5. Leukemia
    • 6.5.6. Lymphoma
    • 6.5.7. Ovarian Cancer
    • 6.5.8. Pancreatic Cancer
    • 6.5.9. Others
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 6.6.1. Oral
    • 6.6.2. Parenteral
    • 6.6.3. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 6.7.1. Capsules/Tablets
    • 6.7.2. Injections
    • 6.7.3. Others
  • 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 6.8.1. Retail Pharmacies
    • 6.8.2. Hospital Pharmacies
    • 6.8.3. Oncology Clinics & Infusion Centers
    • 6.8.4. Others
  • 6.9. Market Attractiveness Analysis

7. Europe Chemotherapy Drugs Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Indication
    • 7.2.4. By Route of Administration
    • 7.2.5. By Dosage Form
    • 7.2.6. By Distribution Channel
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 7.4.1. Alkylating Agents
    • 7.4.2. Antimetabolites
    • 7.4.3. Anti-tumour Antibiotics
    • 7.4.4. Topoisomerase Inhibitors
    • 7.4.5. Mitotic Inhibitors
    • 7.4.6. Plant Alkaloids
    • 7.4.7. Corticosteroids
    • 7.4.8. Miscellaneous Antineoplastic
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 7.5.1. Lung Cancer
    • 7.5.2. Breast Cancer
    • 7.5.3. Colorectal Cancer
    • 7.5.4. Prostate Cancer
    • 7.5.5. Leukemia
    • 7.5.6. Lymphoma
    • 7.5.7. Ovarian Cancer
    • 7.5.8. Pancreatic Cancer
    • 7.5.9. Others
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 7.6.1. Oral
    • 7.6.2. Parenteral
    • 7.6.3. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 7.7.1. Capsules/Tablets
    • 7.7.2. Injections
    • 7.7.3. Others
  • 7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 7.8.1. Retail Pharmacies
    • 7.8.2. Hospital Pharmacies
    • 7.8.3. Oncology Clinics & Infusion Centers
    • 7.8.4. Others
  • 7.9. Market Attractiveness Analysis

8. East Asia Chemotherapy Drugs Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Indication
    • 8.2.4. By Route of Administration
    • 8.2.5. By Dosage Form
    • 8.2.6. By Distribution Channel
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 8.4.1. Alkylating Agents
    • 8.4.2. Antimetabolites
    • 8.4.3. Anti-tumour Antibiotics
    • 8.4.4. Topoisomerase Inhibitors
    • 8.4.5. Mitotic Inhibitors
    • 8.4.6. Plant Alkaloids
    • 8.4.7. Corticosteroids
    • 8.4.8. Miscellaneous Antineoplastic
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 8.5.1. Lung Cancer
    • 8.5.2. Breast Cancer
    • 8.5.3. Colorectal Cancer
    • 8.5.4. Prostate Cancer
    • 8.5.5. Leukemia
    • 8.5.6. Lymphoma
    • 8.5.7. Ovarian Cancer
    • 8.5.8. Pancreatic Cancer
    • 8.5.9. Others
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 8.6.1. Oral
    • 8.6.2. Parenteral
    • 8.6.3. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 8.7.1. Capsules/Tablets
    • 8.7.2. Injections
    • 8.7.3. Others
  • 8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 8.8.1. Retail Pharmacies
    • 8.8.2. Hospital Pharmacies
    • 8.8.3. Oncology Clinics & Infusion Centers
    • 8.8.4. Others
  • 8.9. Market Attractiveness Analysis

9. South Asia & Oceania Chemotherapy Drugs Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Indication
    • 9.2.4. By Route of Administration
    • 9.2.5. By Dosage Form
    • 9.2.6. By Distribution Channel
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 9.4.1. Alkylating Agents
    • 9.4.2. Antimetabolites
    • 9.4.3. Anti-tumour Antibiotics
    • 9.4.4. Topoisomerase Inhibitors
    • 9.4.5. Mitotic Inhibitors
    • 9.4.6. Plant Alkaloids
    • 9.4.7. Corticosteroids
    • 9.4.8. Miscellaneous Antineoplastic
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 9.5.1. Lung Cancer
    • 9.5.2. Breast Cancer
    • 9.5.3. Colorectal Cancer
    • 9.5.4. Prostate Cancer
    • 9.5.5. Leukemia
    • 9.5.6. Lymphoma
    • 9.5.7. Ovarian Cancer
    • 9.5.8. Pancreatic Cancer
    • 9.5.9. Others
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 9.6.1. Oral
    • 9.6.2. Parenteral
    • 9.6.3. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 9.7.1. Capsules/Tablets
    • 9.7.2. Injections
    • 9.7.3. Others
  • 9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 9.8.1. Retail Pharmacies
    • 9.8.2. Hospital Pharmacies
    • 9.8.3. Oncology Clinics & Infusion Centers
    • 9.8.4. Others
  • 9.9. Market Attractiveness Analysis

10. Latin America Chemotherapy Drugs Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Indication
    • 10.2.4. By Route of Administration
    • 10.2.5. By Dosage Form
    • 10.2.6. By Distribution Channel
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 10.4.1. Alkylating Agents
    • 10.4.2. Antimetabolites
    • 10.4.3. Anti-tumour Antibiotics
    • 10.4.4. Topoisomerase Inhibitors
    • 10.4.5. Mitotic Inhibitors
    • 10.4.6. Plant Alkaloids
    • 10.4.7. Corticosteroids
    • 10.4.8. Miscellaneous Antineoplastic
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 10.5.1. Lung Cancer
    • 10.5.2. Breast Cancer
    • 10.5.3. Colorectal Cancer
    • 10.5.4. Prostate Cancer
    • 10.5.5. Leukemia
    • 10.5.6. Lymphoma
    • 10.5.7. Ovarian Cancer
    • 10.5.8. Pancreatic Cancer
    • 10.5.9. Others
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 10.6.1. Oral
    • 10.6.2. Parenteral
    • 10.6.3. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 10.7.1. Capsules/Tablets
    • 10.7.2. Injections
    • 10.7.3. Others
  • 10.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 10.8.1. Retail Pharmacies
    • 10.8.2. Hospital Pharmacies
    • 10.8.3. Oncology Clinics & Infusion Centers
    • 10.8.4. Others
  • 10.9. Market Attractiveness Analysis

11. Middle East & Africa Chemotherapy Drugs Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Indication
    • 11.2.4. By Route of Administration
    • 11.2.5. By Dosage Form
    • 11.2.6. By Distribution Channel
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 11.4.1. Alkylating Agents
    • 11.4.2. Antimetabolites
    • 11.4.3. Anti-tumour Antibiotics
    • 11.4.4. Topoisomerase Inhibitors
    • 11.4.5. Mitotic Inhibitors
    • 11.4.6. Plant Alkaloids
    • 11.4.7. Corticosteroids
    • 11.4.8. Miscellaneous Antineoplastic
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 11.5.1. Lung Cancer
    • 11.5.2. Breast Cancer
    • 11.5.3. Colorectal Cancer
    • 11.5.4. Prostate Cancer
    • 11.5.5. Leukemia
    • 11.5.6. Lymphoma
    • 11.5.7. Ovarian Cancer
    • 11.5.8. Pancreatic Cancer
    • 11.5.9. Others
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 11.6.1. Oral
    • 11.6.2. Parenteral
    • 11.6.3. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 11.7.1. Capsules/Tablets
    • 11.7.2. Injections
    • 11.7.3. Others
  • 11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 11.8.1. Retail Pharmacies
    • 11.8.2. Hospital Pharmacies
    • 11.8.3. Oncology Clinics & Infusion Centers
    • 11.8.4. Others
  • 11.9. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. F. Hoffmann-La Roche Ltd
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Product Types
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Celgene Corp
    • 12.3.3. Novartis AG
    • 12.3.4. Bristol-Myers Squibb Co
    • 12.3.5. Johnson & Johnson
    • 12.3.6. Sanofi
    • 12.3.7. Pfizer Inc.
    • 12.3.8. Eli Lilly & Company
    • 12.3.9. ImClone Systems Inc.
    • 12.3.10. GlaxoSmithKline
    • 12.3.11. AstraZeneca
    • 12.3.12. Schering-Plough
    • 12.3.13. Boehringer Ingelheim
    • 12.3.14. Bristol-Myers Squibb
    • 12.3.15. Teva Pharmaceuticals Industries
    • 12.3.16. E. Hoffmann-La Roche Ltd
    • 12.3.17. Merck & Co. Inc.
    • 12.3.18. Chemo Espana SL
    • 12.3.19. Amgen Inc
    • 12.3.20. Bayer AG
    • 12.3.21. Takeda Pharmaceutical Company Limited

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations